Clinical Trial Detail

NCT ID NCT02514174
Title Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
Recruitment Completed
Gender both
Phase FDA approved
Variant Requirements No
Sponsors Boehringer Ingelheim
Indications

lung non-small cell carcinoma

Therapies

Afatinib

Age Groups: senior

No variant requirements are available.